Catalyst Biosciences (NASDAQ: CBIO) and Vitae Pharmaceuticals (NASDAQ:VTAE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitabiliy, risk, dividends and earnings.

Earnings and Valuation

This table compares Catalyst Biosciences and Vitae Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Catalyst Biosciences $560,999.00 28.10 -$18.69 million ($17.78) -0.21
Vitae Pharmaceuticals N/A N/A N/A ($1.93) -10.88

Vitae Pharmaceuticals has higher revenue, but lower earnings than Catalyst Biosciences. Vitae Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Catalyst Biosciences has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Vitae Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.


This table compares Catalyst Biosciences and Vitae Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalyst Biosciences -3,127.92% -92.61% -46.69%
Vitae Pharmaceuticals -318,350.20% -53.70% -49.85%

Analyst Ratings

This is a summary of recent recommendations for Catalyst Biosciences and Vitae Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalyst Biosciences 0 0 3 0 3.00
Vitae Pharmaceuticals 0 5 0 0 2.00

Catalyst Biosciences currently has a consensus target price of $24.50, suggesting a potential upside of 562.16%. Vitae Pharmaceuticals has a consensus target price of $21.67, suggesting a potential upside of 3.17%. Given Catalyst Biosciences’ stronger consensus rating and higher probable upside, research analysts plainly believe Catalyst Biosciences is more favorable than Vitae Pharmaceuticals.

Insider and Institutional Ownership

5.6% of Catalyst Biosciences shares are owned by institutional investors. Comparatively, 72.6% of Vitae Pharmaceuticals shares are owned by institutional investors. 5.0% of Catalyst Biosciences shares are owned by insiders. Comparatively, 14.8% of Vitae Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Catalyst Biosciences beats Vitae Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Catalyst Biosciences

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer’s disease, or Alzheimer’s. VTP-43742, the Company’s wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Receive News & Ratings for Catalyst Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc. and related companies with's FREE daily email newsletter.